In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile.
AUTOR(ES)
Fasola, E L
RESUMO
The in vitro activity of LY 264826, a new glycopeptide antibiotic, was compared with that of vancomycin against 100 strains each of methicillin-resistant Staphylococcus aureus and Clostridium difficile. LY 264826 was more active, by weight, than vancomycin against the isolates tested. The human serum protein binding of LY 264826 was 15.3% (range, 9.8 to 21.8%).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171979Documentos Relacionados
- Interaction study between vancomycin and liposomes containing natural compounds against methicillin-resistant Staphylococcus aureus clinical isolates
- Comparative in vitro activity of coumermycin against methicillin-resistant Staphylococcus aureus.
- Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.
- Efficacy of LY333328 against Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis
- In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.
